Structures by: Yin L. H.
Total: 15
C60H61Cl2FeN10NiO20P2
C60H61Cl2FeN10NiO20P2
Journal of the Chemical Society, Dalton Transactions (2001) 9 1398
a=17.3028(15)Å b=20.5989(19)Å c=20.1296(19)Å
α=90.00° β=111.796(2)° γ=90.00°
(S)-Diethyl {(4-fluorophenyl)[5-(4-methoxyphenyl)-1,3,4-thiadiazol-2- ylamino]methyl}phosphonate
C20H23FN3O4PS
Acta Crystallographica Section E (2007) 63, 10 o4158-o4158
a=9.4140(19)Å b=10.227(2)Å c=12.923(3)Å
α=110.44(3)° β=98.80(3)° γ=100.58(3)°
(R,S)-Diethyl {[5-(2,4-dichlorophenyl)-1,3,4-thiadiazol-2-ylamino](phenyl)methyl}phosphonate
C19H20Cl2N3O3PS
Acta Crystallographica Section E (2007) 63, 12 o4648-o4648
a=8.4870(17)Å b=16.530(3)Å c=15.703(3)Å
α=90.00° β=94.47(3)° γ=90.00°
Triflumuron
C15H10ClF3N2O3
Acta Crystallographica Section E (2008) 64, 7 o1218
a=17.293(4)Å b=8.2870(17)Å c=11.073(2)Å
α=90.00° β=101.74(3)° γ=90.00°
2-(2,4-Dichlorophenyl)-3-[5-(4-methoxyphenyl)-1,3,4-thiadiazol-2-yl]-1,3- thiazolidin-4-one
C18H13Cl2N3O2S2
Acta Crystallographica Section E (2008) 64, 5 o795
a=7.1310(14)Å b=8.1540(16)Å c=16.671(3)Å
α=93.19(3)° β=96.43(3)° γ=105.89(3)°
Dichloridobis(5-<i>m</i>-tolyl-1,3,4-thiadiazol-2-ylamine-κN^3^)zinc(II)
C18H18Cl2N6S2Zn
Acta Crystallographica Section E (2008) 64, 5 m692-m693
a=10.826(2)Å b=11.233(2)Å c=17.892(4)Å
α=90.00° β=90.10(3)° γ=90.00°
3-[5-(4-Fluorophenyl)-1,3,4-thiadiazol-2-yl]-2-(4-methoxyphenyl)- 1,3-thiazolidin-4-one
C18H14FN3O2S2
Acta Crystallographica Section E (2008) 64, 7 o1359
a=6.4550(13)Å b=8.9200(18)Å c=16.483(3)Å
α=75.78(3)° β=82.44(3)° γ=71.11(3)°
2-Methoxy-<i>N</i>-[5-(2-methoxyphenyl)-1,3,4-thiadiazol-2-yl]benzamide hemihydrate
C17H15N3O3S,0.5(H2O)
Acta Crystallographica Section E (2008) 64, 8 o1637
a=29.950(6)Å b=14.561(3)Å c=7.6520(15)Å
α=90.00° β=94.78(3)° γ=90.00°
2-(2,4-Dichlorophenyl)-3-[5-(3,5-dimethylphenyl)-1,3,4-thiadiazol-2- yl]thiazolidin-4-one
C19H15Cl2N3OS2
Acta Crystallographica Section E (2008) 64, 1 o260-o260
a=8.1760(16)Å b=9.1650(18)Å c=14.483(3)Å
α=80.60(3)° β=80.82(3)° γ=63.92(3)°
5-(2-Bromophenyl)-1,3,4-thiadiazol-2-amine
C8H6BrN3S
Acta Crystallographica Section E (2008) 64, 10 o1884
a=14.869(3)Å b=8.0250(16)Å c=7.9480(16)Å
α=90.00° β=97.43(3)° γ=90.00°
Methyl 2-{[3-(4,6-dimethoxypyrimidin-2-yl)ureido]sulfonylmethyl}benzoate
C16H18N4O7S
Acta Crystallographica Section E (2008) 64, 3 o632
a=33.831(7)Å b=6.9020(14)Å c=16.021(3)Å
α=90.00° β=104.48(3)° γ=90.00°
<i>N</i>-{(<i>E</i>)-4-[(<i>E</i>)-(Dodecylimino)methyl]benzylidene}dodecan-\ 1-imine ?
C32H56N2
Acta Crystallographica Section E (2008) 64, 3 o565
a=4.7370(9)Å b=5.5190(11)Å c=30.315(6)Å
α=91.18(3)° β=93.44(3)° γ=101.75(3)°
Diethyl {(4-methoxyphenyl)[5-(4-nitrophenyl)-1,3,4-thiadiazol-2- ylamino]methyl}phosphonate
C20H23N4O6PS
Acta Crystallographica Section E (2008) 64, 8 o1376
a=11.481(2)Å b=19.426(4)Å c=11.960(2)Å
α=90.00° β=117.08(3)° γ=90.00°
(9S,13R,14S)-7,8-didehydro-3,4,7-trimethoxy-N-methyl-morphinan-6-one
C20H25NO4
Acta Crystallographica Section E (2009) 65, 4 o689
a=10.9590(15)Å b=10.9590(15)Å c=12.726(3)Å
α=90.00° β=90.00° γ=120.00°
Diethyl {[5-(2,4-dichlorophenyl)-1,3,4-thiadiazol-2-ylamino](4- methoxyphenyl)methyl}phosphonate
C20H22Cl2N3O4PS
Acta Crystallographica Section E (2009) 65, 5 o983
a=9.7100(19)Å b=11.825(2)Å c=11.845(2)Å
α=98.74(3)° β=112.16(3)° γ=103.05(3)°